Skip to main
ATAI

ATAI Stock Forecast & Price Target

ATAI Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atai Beckley NV's clinical data for BPL-003 indicates significant improvements in mental health outcomes, reporting enhanced mean Montgomery-Asberg Depression Rating Scale (MADRS) scores and doubled remission rates after subsequent doses, which supports the program's advancement. The company is projected to capture approximately 20% of the market share for treatment-resistant depression by 2035, thanks to its clinical differentiation and expedited time to market. Additionally, with BPL-003 displaying favorable response rates and a potential commercially advantageous time post-dose if approved, the ongoing clinical developments suggest sustained investor interest and potential for further stock appreciation.

Bears say

Atai Beckley NV's clinical data indicates a concerning decline in efficacy for its key treatment candidates, particularly observing a reduction in patient outcomes from Week 4 to Week 6 across trials. Specifically, the change in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores demonstrated that results from its therapies, such as BPL-003, fell short of competitive benchmarks, particularly when compared to established treatments like Spravato. Additionally, the potential safety risks emerging from limited data on induction doses further compound the negative outlook for Atai Beckley's stock, suggesting uncertainty surrounding both efficacy and safety of its drug candidates.

ATAI has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atai Life Sciences BV (ATAI) Forecast

Analysts have given ATAI a Strong Buy based on their latest research and market trends.

According to 5 analysts, ATAI has a Strong Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atai Life Sciences BV (ATAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.